Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rifaximin AND Placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Rifaximin AND Placebo. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-001856-51 Sponsor Protocol Number: 12.007 Start Date*: 2014-08-26
    Sponsor Name:Aleksander Krag
    Full Title: Anti-fibrotic and molecular aspects of rifaximin in alcoholic liver disease: A randomized placebo controlled clinical trial
    Medical condition: Liver fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10016648 Fibrosis liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-006814-35 Sponsor Protocol Number: MoodBugs_Rifaximin Start Date*: 2022-09-27
    Sponsor Name:KU Leuven
    Full Title: A randomized, triple-blind, placebo-controlled study on the effect of rifaximin on psychobiological functions in healthy men
    Medical condition: Experimental study with healthy participants recruited from the general population; no vulnerable individuals or clinical groups will be involved. Our objective is to test whether rifaximin adminis...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-003986-42 Sponsor Protocol Number: Rifa1 Start Date*: 2008-06-18
    Sponsor Name:University Hospital of Tübingen
    Full Title: Prospective, randomised, placebo controlled, double blind monocenter trial for the prophylactic treatment of diarrhoea with rifaximin for travellers to South- and Southeast-Asia
    Medical condition: diarrhoea of travellers to South- and Southeast-Asia
    Disease: Version SOC Term Classification Code Term Level
    12.0 10021907 Infectious diarrhea LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002258-36 Sponsor Protocol Number: RETIPC/01/17 Start Date*: 2017-11-21
    Sponsor Name:ALFASIGMA S.P.A.
    Full Title: A Phase II, multicentre, double-blind, randomised, placebo-controlled study of Rifaximin delayed release 400 mg tablet: clinical efficacy and safety in the prevention of post-operative endoscopic C...
    Medical condition: Post-operative endoscopic Crohn’s disease recurrence
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003205-10 Sponsor Protocol Number: 12072 Start Date*: 2012-09-17
    Sponsor Name:University of Nottingham
    Full Title: A randomised placebo controlled trial of follow on Rifaximin for the prevention of relapse of Clostridium difficile associated diarrhoea.
    Medical condition: C.Difficile antibiotic-associated diarrhoeal infection
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001645-24 Sponsor Protocol Number: RECD3126 Start Date*: 2014-11-18
    Sponsor Name:Salix Pharmaceuticals, Inc.
    Full Title: A Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction ...
    Medical condition: Treatment of active Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001644-38 Sponsor Protocol Number: RECD3125 Start Date*: 2014-11-18
    Sponsor Name:Salix Pharmaceuticals, Inc.
    Full Title: A Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction ...
    Medical condition: Treatment of active Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002708-28 Sponsor Protocol Number: REDIV/002/17 Start Date*: 2018-02-23
    Sponsor Name:Alfasigma S.p.a
    Full Title: Rifaximin delayed release (400 mg tablet) for the prevention of recurrent acute diverticulitis and diverticular complications. A phase II, multicenter, double-blind, placebo-controlled, randomized ...
    Medical condition: Prevention of recurrent acute diverticulitis and diverticular complications
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10052812 Acute diverticulitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) HU (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) PT (Completed) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-003722-33 Sponsor Protocol Number: REROS/001/17 Start Date*: 2018-03-02
    Sponsor Name:ALFASIGMA S.P.A.
    Full Title: Safety and Efficacy of Rifaximin Delayed Release 400 mg Tablets in Patients with Moderate-to-Severe Papulopustular Rosacea and Positive Lactulose Breath Test. A Multicenter Double-Blind, Placebo-Co...
    Medical condition: Moderate-to-Severe Papulopustular Rosacea and Positive Lactulose Breath Test
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10076537 Papulopustular rosacea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001891-39 Sponsor Protocol Number: version4.6,29082018 Start Date*: 2018-09-14
    Sponsor Name:XiCoCo study group
    Full Title: Rifaximin-treatment of Collagenous colitis: A prospective, double-blind, placebo-controlled study
    Medical condition: Collagenous Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10048928 Colitis collagenous LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-004708-20 Sponsor Protocol Number: RIFSYS Start Date*: 2014-03-27
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King's College Hospital NHS Foundation Trust
    Full Title: A placebo controlled single centre double blind randomised trial to investigate the efficacy of rifaximin versus placebo in improving systemic inflammation and neutrophil malfunction in patients wi...
    Medical condition: Cirrhosis and chronic hepatic encephalopathy
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004871 10024667 Liver cirrhosis LLT
    18.0 10029205 - Nervous system disorders 10019660 Hepatic encephalopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000357-41 Sponsor Protocol Number: APC040 Start Date*: 2013-08-28
    Sponsor Name:The Alimentary Pharmabiotic Centre, University College Cork
    Full Title: Identification of the Microbiota Dependent Response to Rifaximin in Irritable Bowel Syndrome Patients
    Medical condition: Irritable Bowel Syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011826-32 Sponsor Protocol Number: RFX-VAG/002/2008 Start Date*: Information not available in EudraCT
    Sponsor Name:Alfa Wassermann S.p.A.
    Full Title: A phase II, multicentre, double-blind, randomised, placebo-controlled study on efficacy and tolerability of Rifaximin vaginal tablets in the treatment of bacterial vaginosis
    Medical condition: Bacterial vaginosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004055 Bacterial vaginosis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004159-56 Sponsor Protocol Number: MERISUDD Start Date*: 2017-10-12
    Sponsor Name:DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: Efficacy and safety of mesalazine, rifaximin, alone or as extemporary combination, in the treatment of symptomatic uncomplicated diverticular disease of colon: multi-centre, randomised, double-blin...
    Medical condition: Treatment of symptomatic uncomplicated diverticular colon disease (SUDD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10013538 Diverticulitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001014-17 Sponsor Protocol Number: RETIC/03/06 Start Date*: 2007-07-26
    Sponsor Name:Alfa Wassermann S.p.A.
    Full Title: A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active...
    Medical condition: Treatment of moderate, active Crohn’s disease: induction of remission.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011401 Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004499-23 Sponsor Protocol Number: LIVERHOPE_SAFETY Start Date*: 2017-03-10
    Sponsor Name:IDIBAPS
    Full Title: Safety and tolerability of the combination of simvastatin plus rifaximin in patients with decompensated cirrhosis: a multicenter, double-blind, placebo controlled randomized clinical trial.
    Medical condition: Patients with decompensated cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10019805 - Hepatobiliary disorders 10019641 Hepatic cirrhosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001698-25 Sponsor Protocol Number: LIVERHOPE_EFFICACY Start Date*: 2018-07-24
    Sponsor Name:IDIBAPS
    Full Title: Efficacy of the combination of simvastatin plus rifaximin in patients with decompensated cirrhosis to prevent ACLF development: a multicenter, double-blind, placebo controlled randomized clinical t...
    Medical condition: Patients with decompensated cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10009209 Cirrhosis bilary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed) FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004323-37 Sponsor Protocol Number: PEARL-trial Start Date*: 2019-06-06
    Sponsor Name:Academic Medical Centre
    Full Title: Prevention of hepatic Encephalopathy by Administration of Rifaximin and Lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt: a multi-c...
    Medical condition: post-TIPS Hepatic Encephalopathy (HE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10019660 Hepatic encephalopathy PT
    20.0 10029205 - Nervous system disorders 10076204 Minimal hepatic encephalopathy PT
    20.1 10042613 - Surgical and medical procedures 10066599 Hepatic encephalopathy prophylaxis PT
    21.1 10042613 - Surgical and medical procedures 10068826 Transjugular intrahepatic portosystemic shunt LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004578-27 Sponsor Protocol Number: A3921094 Start Date*: 2012-04-26
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, New York 10017
    Full Title: A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) DK (Completed) HU (Completed) EE (Completed) LV (Completed) DE (Completed) BE (Completed) ES (Completed) NL (Completed) AT (Completed) SK (Completed) PL (Completed) IT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004579-35 Sponsor Protocol Number: A3921095 Start Date*: 2012-05-01
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, New York 10017
    Full Title: A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
    Medical condition: Moderate to severe active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) HU (Completed) EE (Completed) DK (Completed) LV (Completed) BE (Completed) ES (Completed) NL (Completed) AT (Completed) DE (Completed) SK (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:30:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA